Perinatal Cardiovascular Features and Angiotensin System Expressions in Maternal Preeclampsia

Heyansh Kreiselukas

Keywords

Preeclampsia • Perinatal cardiovascular features • Angiotensin system • Pregnancy complications

Introduction

Preeclampsia is a pregnancy-specific disorder characterized by the onset of hypertension and proteinuria after 20 weeks of gestation, affecting 5-8% of pregnancies worldwide. Despite extensive research, its pathogenesis remains incompletely understood, but dysregulation of the Renin-Angiotensin System (RAS) is implicated. The RAS, critical in regulating blood pressure and fluid balance, undergoes alterations in preeclampsia, contributing to endothelial dysfunction, vasoconstriction and hypertension. In maternal preeclampsia, the placenta releases factors that promote systemic inflammation and impair vascular endothelial function, leading to increased vascular resistance and hypertension. The imbalance in vasoactive substances, including angiotensin II and its receptors, further exacerbates vascular dysfunction and organ damage in affected individuals. Understanding the interplay between perinatal cardiovascular features and RAS expressions in preeclampsia is crucial for identifying biomarkers, predicting disease severity and developing targeted interventions to mitigate maternal and fetal complications. This study aims to elucidate the association between perinatal cardiovascular features, such as maternal blood pressure dynamics, fetal growth patterns and placental function, with RAS expressions in maternal preeclampsia. We seek to uncover novel insights into the mechanistic pathways linking cardiovascular adaptations and RAS dysregulation in the pathophysiology of preeclampsia. Ultimately, this research contributes to advancing personalized approaches in managing hypertensive disorders of pregnancy and improving maternal-fetal outcomes [1,2].

Literature Review

Preeclampsia remains a significant cause of maternal and perinatal morbidity and mortality worldwide, characterized by new-onset hypertension and proteinuria after 20 weeks of gestation. The pathophysiology of preeclampsia involves complex interactions between placental factors, maternal vascular dysfunction and dysregulation of the Renin-Angiotensin System (RAS). Studies have shown that in preeclampsia, there is an imbalance in the production and sensitivity to vasoactive substances, including angiotensin II, which contributes to endothelial dysfunction, increased vascular resistance and hypertension. Research has focused on understanding how perinatal cardiovascular features, such as maternal blood pressure variability, fetal growth patterns and placental function, correlate with alterations in the angiotensin system during preeclampsia. Additionally, investigations into the expression of Angiotensin Receptors (AT1R and AT2R) in placental tissues have highlighted their role in mediating vasoconstriction and placental vascular function in preeclampsia. Despite advancements in understanding the molecular mechanisms underlying RAS dysregulation in preeclampsia, gaps remain in translating these findings into clinical practice. The variability in study designs, patient populations and methodologies underscores the need for standardized approaches to comprehensively assess the interplay between perinatal cardiovascular features and RAS expressions in maternal preeclampsia [3,4].

Discussion

The discussion revolves around the complexities of studying perinatal cardiovascular features and RAS expressions in maternal preeclampsia. Evidence suggests that the dysregulation of the RAS contributes to maternal hypertension and endothelial dysfunction, impacting fetal growth and development. Perinatal cardiovascular adaptations, such as altered maternal blood pressure profiles and placental vascular resistance, reflect underlying disturbances in RAS signaling pathways, which may serve as biomarkers for predicting preeclampsia severity and perinatal outcomes. Furthermore, the role of angiotensin II and its receptors in mediating vasoconstriction and oxidative stress in preeclampsia underscores potential therapeutic targets for managing maternal hypertension and improving fetal health. Strategies aimed at modulating RAS activity, such as Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs), have shown promise in preclinical studies for mitigating hypertension and reducing adverse perinatal outcomes associated with preeclampsia. However, clinical trials evaluating the safety and efficacy of RAS-targeted therapies in pregnant women are warranted to guide evidence-based management strategies. From a clinical perspective, integrating comprehensive prenatal care protocols that include monitoring of maternal blood pressure dynamics and biomarkers of RAS activity may enhance early detection and management of preeclampsia. Multidisciplinary collaborations between obstetricians, nephrologists and perinatologists are essential for optimizing maternal-fetal outcomes and reducing the global burden of hypertensive disorders in pregnancy [5,6].

Conclusion

In conclusion, perinatal cardiovascular features and angiotensin system expressions play integral roles in the pathophysiology of maternal preeclampsia. Literature highlights the intricate relationships between maternal hypertension, placental dysfunction and dysregulated RAS signaling pathways, underscoring their collective impact on fetal health and pregnancy outcomes. Advances in understanding these interactions offer promising avenues for developing targeted interventions aimed at improving maternal cardiovascular health and optimizing fetal growth in preeclamptic pregnancies. Future research efforts should focus on elucidating the specific mechanisms by which perinatal cardiovascular adaptations influence RAS activity and vice versa. By addressing knowledge gaps and leveraging translational research approaches, we can enhance diagnostic precision, refine therapeutic strategies and ultimately mitigate the adverse maternal and perinatal consequences associated with preeclampsia.

Acknowledgment

None.

Conflict of Interest

No conflict of interest.

References

1. Hodgins, Stephen. "Pre-eclampsia as underlying cause for perinatal deaths: Time for action." Glob Health Sci Pract 3 (2015): 525-527.

Google Scholar, Crossref, Indexed at

2. Stojanovska, Violeta, Sicco A. Scherjon and Torsten Plösch. "Preeclampsia as modulator of offspring health." Biol Reprod 94 (2016): 53-1.

Google Scholar, Crossref, Indexed at

3. Palinski, Wulf. "Effect of maternal cardiovascular conditions and risk factors on offspring cardiovascular disease." Circulation 129 (2014): 2066-2077.

Google Scholar, Crossref, Indexed at

4. Yang, Chuyu, Philip N. Baker, Joey P. Granger and Sandra T. Davidge, et al. "Long-term impacts of preeclampsia on the cardiovascular system of mother and offspring." Hypertension 80 (2023): 1821-1833.

Google Scholar, Crossref, Indexed at

5. Geelhoed, JJ Miranda, Abigail Fraser, Kate Tilling and Li Benfield, et al. "Preeclampsia and gestational hypertension are associated with childhood blood pressure independently of family adiposity measures: The Avon Longitudinal Study of Parents and Children." Circulation 122 (2010): 1192-1199.

Google Scholar, Crossref, Indexed at

6. Visentin, Silvia, Ambrogio Pietro Londero, Beatrice Bellamio and Grazia Giunta, et al. "Fetal endothelial remodeling in late-onset gestational hypertension." Am J Hypertens 29 (2016): 273-279.

Google Scholar, Crossref, Indexed at